

بسم الله الرحمن الرحيم





شبكة المعلومات الجامعية التوثيق الالكتروني والميكروفيلم



جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار





Department of Physics

Enhancement of Drug Release Efficiency Using Magnetic Nano composite

A Thesis submitted in partial fulfillment of the requirements for the
degree of

Master of Science in Biophysics

By

Alaa Al Rahaman Gamal Saad Ahmed

B.Sc. Biophysics, Faculty of science, Ain Shams University 2013

Under Supervision of:

Prof .Dr. El-Sayed Mahmoud El-Sayed

Professor of Biophysics – Department of Physics
Faculty of Science – Ain Shams University

Dr. Heba Mahmoud Ebrahim Kahil

Lecturer of Biophysics – Department of Physics
Faculty of Science – Ain Shams University

Dr. Tarek Ahmed Ali El-Hamouly

Lecturer of Drug Radiation Research Department, National Center for Radiation Research and Technology, Egyptian Atomic Energy Authority

Cairo, Egypt

2022



APPROVAL SHEET

Enhancement of Drug Release Efficiency Using Magnetic Nano composite

A Thesis submitted in partial fulfillment of the requirements for the
degree of **Master of Science in Biophysics**

By

Alaa Al Rahaman Gamal Saad Ahmed

Supervisors

Signature

Prof .Dr. El-Sayed Mahmoud El-Sayed

(.....)

Professor of Biophysics

Department of Physics, Faculty of Science-ASU

Dr. Heba Mahmoud Ebrahim Kahil

(.....)

Lecturer of Biophysics – Department of Physics

Faculty of Science – Ain Shams University

Dr. Tarek Ahmed Ali El-Hamouly

(.....)

Lecturer of Drug Radiation Research Department,

National Center for radiation Research and Technology, Egyptian Atomic
Energy Authority

Cairo, Egypt
2022

Ain Shams University
Faculty of Science
Physics Department



Enhancement of Drug Release Efficiency Using Magnetic Nano composite

A Thesis submitted in partial fulfillment of the requirements for the
degree of **Master of Science in Biophysics**

By:

Alaa Al Rahaman Gamal Saad Ahmed

Examiners Committee

Signature

Prof .Dr. El-Sayed Mahmoud El-Sayed

Prof. Dr. Reem Hassan Nour El-Deen El-Gebaly

Prof. Dr. Abeer Mohamed Ameen Ali

**Cairo, Egypt
2022**

Ain Shams University
Faculty of Science
Physics Department



Researcher Data

Name: Alaa Al Rahaman Gamal Saad Ahmed

Degree: M. Sc

Department: Physics

Faculty: Science

University: Ain Shams

Graduation date: 2013 –Ain Shams University

Field of specialization: Science, Biophysics

Current Job: Demonstrator, Physics department

Registration date: 10/7/2017

Grant date: 2022

Cairo, Egypt
2022

Acknowledgement

All thanks to **Allah** for giving me the courage and fortitude to complete this work.

I would like to express my heartfelt gratitude and deepest appreciation to my supervisor, **Prof .Dr. El-Sayed Mahmoud El-Sayed** for his invaluable advice and support throughout my work. Without your understanding and patience, none of this would have been possible.

I am grateful from the core of my heart to my supervisor **Dr. Heba Mahmoud Ebrahim Kahil** for suggesting this fruitful point of research guidance, devotion, and promotion for completion of this work, her brilliant ideas, guidance, and mentoring helped me overcome many hurdles throughout my Master's research.

I would like to extend my thanks to **my supervisor Dr. Tarek Ahmed Ali El-Hamouly** for his great effort and support for me in my work, his great ideas on how to complete the required work.

Thanks to **all members of the biophysics group**. Physics Department, Faculty of Science, Ain Shams University for their cooperation.

I would like to thank my wonderful husband, assistance. Prof. Mohamed Mostafa has been there for me through the toughest of times and completely supporting my dreams.

Last but most importantly, I want to thank my parents, who have sacrificed much to ensure that I have the best in life and my beautiful children Anas, Hamza, and Nouran.

Contents

Abstract	1
1. Introduction and literature review	1
1.1. Introduction	1
1.2. Literature review	6
1.2.1. Biomedical application of magnetic nanoparticles	6
1.2.2. Synthesis of magnetic nanocomposite	13
1.2.3. Encapsulation of SPIONs in thermoresponsive polymer	15
1.2.4. Magnetic thermoresponsive nanocomposite as drug delivery systems DDS	18
1.2.5. Biocompatibility of magnetic thermoresponsive nanocomposites	23
1.3. Plan of work	24
2. Theoretical aspects	26
2.1. Colorectal carcinoma (CRC)	26
2.2. PARP and PARP inhibitor	28
2.3. Hyperthermia as a therapeutic modality	31
2.3.1. Magnetic fluid hyperthermia	31
2.3.2. Tumor micro environment	32
2.3.3. The effect of heating on tumor tissue	33
2.4. Theoretical background of magnetic hyperthermia	34
2.4.1. Crystal structure of iron oxide nanoparticles	34
2.4.2. Ferrimagnetism in iron oxide	36
2.4.3. Magnetization in bulk material	38
2.4.4. Single domain structure	44
2.4.5. Superparamagnetism (SPM)	45
2.4.6. Relaxation mechanisms	46
2.4.7. Specific absorption rate (SAR)	48
2.5. Smart polymer; drug delivery and controlled drug release	49

TABLE OF CONTENTS

2.5.1.	Drug delivery	50
2.5.2.	Thermoresponsive polymer; structure and properties	51
2.5.3.	In situ free radical polymerization	53
3.	Materials and Methods	56
3.1.	Materials	56
3.2.	Methods	57
3.2.1.	Synthesis of superparamagnetic iron oxide nanoparticles (SPIONs).....	57
3.2.2.	Synthersis of poly(N-isopropylacrylamide) (PNIPAAm)	57
3.2.3.	Synthesis of magnetic thermoresponsive nanoco mposites (MTNs)	58
3.3.	Characterization of magnetite and MTN	59
3.3.1.	Structural analysis	59
3.3.2.	Phase transition measurements	65
3.3.3.	Magnetic characterization	67
3.4.	Drug loading.....	71
3.5.	Drug release	72
3.6.	In vivo study	74
	Kidney and liver functions	75
	Histological examinations	75
3.7.	In vitro study	75
3.7.1.	MTT assay	75
3.7.2.	In vitro cytotoxicity study	76
4.	Results and discussion	78
4.1.	Structural analysis	78
4.1.1.	X-ray diffraction	78
4.1.2.	Scanning electron microscope SEM and Electron dispersive X-ray spectroscopy	80
4.1.3.	High resolution transmission electron microscopy (HRTEM).....	82

TABLE OF CONTENTS

4.1.4.	Fourier transform infrared (FTIR)	85
4.1.5.	Thermal gravimetric analysis (TGA)	86
4.2.	Phase transition temperature measurements	88
4.2.1.	Phase transition temperature measurements of PNIPAAm	89
4.2.2.	Phase transition temperature measurements of MTN and MTN.5-AIQ	90
4.3.	Magnetic characterization	93
4.3.1.	Magnetic properties	93
4.3.2.	Magnetic fluid hyperthermia MFH	96
4.4.	Drug loading	99
4.5.	Drug release	101
4.6.	In vivo study	103
	Kidney and liver functions	103
4.7.	In vitro study	106
5.	Conclusions	108
	References	110

LIST OF FIGURES

List of Figures

Figure 1.1 Schematic representation shows the bimodal therapy, achieved by magnetic thermoresponsive nanocomposite.	5
Figure 1.2 Schematic representation of the biomedical applications of SPIONs.....	7
Figure 2.1 structural representation of PARP1 and its binding with damaged DNA (Jannetti, et al.,2020)	29
Figure 2.2 General chemical mechanism for the poly(ADP-ribosylation) reaction catalyzed by PARPs, with amino-acids in the enzyme numbered as for PARP-1. General pharmacophore for compounds which inhibit PARPs and the structure of 5-aminoisoquinoline 5AIQ (Threadgill, 2015), (Vinod et al, 2010).....	30
Figure 2.3. Schematic representation for vasculature in normal and tumor tissues.....	33
Figure 2.4.The inverse spinel crystal structure of magnetite (Fe_3O_4), showing the FCC close-packing of O^{2-} ions in black, the tetrahedral sites (occupied by Fe^{3+}) in red, and the octahedral sites (occupied by both Fe^{3+} and Fe^{2+}) in blue (Hashimoto, et al, 2019)	35
Figure 2.5 crystal structure of maghemite (Rachna, et al. 2019)	36
Figure 2.6 Conceptual representations of double and super-exchange interaction in Fe_3O_4 through d orbitals of Fe^{+2} and Fe^{+3} cations	37
Figure 2.7. Schematic representation of the overlapping of Fe^{2+} / Fe^{3+} cations and O^{2-} anion 3d- and 2p orbitals	38
Figure 2.8 Spin configuration of Fe^{3+} and Fe^{2+} in both octahedral and tet.....	38
Figure 2.9 Schematic diagram of the free energy of a single domain	40
Figure 2.10. Schematic representation of domains formation; (a) field line in a particle of single domain, (b) formation of domains, (c) closure domain	41
Figure 2.11. Schematic showing the magnetic hysteresis loop.	43
Figure 2.12 Schematic diagram showing the types of magnetic materials (Mody, et al. 2013)	43
Figure 2.13 Schematic illustration for the size effect on the magnetic state of material and its coercivity.....	44
Figure 2.14 Schematic representation for Neel and Brownian relaxation losses	48
Figure 2.15 Schematic showing the problematic drug release and the desirable controlled release	51
Figure 2.16. Schematic representation to synthesis of Poly(N-isopropylacrylamide)	53
Figure 2.17. The most common initiators used for production of free radicals	54

LIST OF FIGURES

Figure 3.1 Schematic representation of synthesis of SPIONs (A) & synthesis of MTNs (B)	58
Figure 3.2 X-ray diffractometer and schematic representation of its main components	60
Figure 3.3 Scanning electron microscope instrument and schematic representation of its component	61
Figure 3.4. Schematic representation of energy dispersive X-ray spectroscopy.....	62
Figure 3.5 High resolution transmission electron microscopy	63
Figure 3.6 Fourier transform spectroscopy (FTIR) instrument.....	64
Figure 3.7. Schematic diagram shows the principle of turbidity measurements; (A) Nephelometer, (B) UV-visible spectrophotometer.....	66
Figure 3.8. Schematic showing of Vibrating Sample Magnetometer.....	68
Figure 3.9. Schematic representation of working coil of the induction heater	70
Figure 3.10. Schematic showing of HPLC components	73
Figure 3.11: (a) The intraperitoneal injection of the mouse, (b)the anatomy of themouse to collect the liver and kidney.	74
Figure 3.12. Reduction of yellow MTT to purple farmazan crystal is indication to viable cells.....	76
Figure 4.1: X-ray powder diffraction patterns of IONPs	79
Figure 4.2: A) SEM image of SPIONs, B) EDX spectrum of SPIONs, C) EDX spectrum of MTN.....	81
Figure 4.3: TEM image of MTN (a) & size distribution curveof SPIONs core (b)	83
Figure 4.4: SAED pattern of magnetic nanocomposite (MTN)	84
Figure 4.5: FTIR spectra of SPIONs and SPIONs -PNIPAM	86
Figure 4.6: The thermogram of MTN sample.....	88
Figure (4.7): (A),(B) Turbidity test for PNIPAAm showing the cloud point T_{CP} of the polymer, (C),(D) and (E) DSC of PNIPAAm ,MTN and MTN.5-AIQ showing the phase transition temperature of the nanocomposites	92
Figure 4.8: M versus H hysteresis loop of magnetite and magnetic nanocomposite(MTN).....	95
Figure 4.9: Temperature time dependence curve for SPIONs sample.	98
Figure 4.10: A) HPLC chromatogram for 5-AIQ, B) drug loading efficiency of MTN samples.....	100
Figure 4.11. 5AIQ release profile OF MNC.5AIQ.4 with temperature; (A) UV-VIS analysis, (B) HPLC analysi	102
Figure 4.12. .Effect of CIS (dose=15 mg/kg) and MTN.5AIQ (dose=5mg/kg) on kidney and liver functions: Serum (A) creatinine, (B) uric acid, (C) glutamic pyruvic transaminase (GPT)and (D) glutamic oxalic transaminase	

LIST OF FIGURES

(GOT) were evaluated for the three experimental groups; CTRL, CIS and MTN.5-AIQ. Each value represents the mean \pm SE (n=5 mice per group), *significantly different versus control group (CTRL) (P<0.05), **significantly different versus control group (P<0.005), ****significantly different versus control group (P<0.0001). CTRL; control, CIS: cisplatin, MTN.5-AIQ; magnetic thermoresponsive nanocomposite loaded with 5-aminoisoquinoline	104
Figure 4.13(A) Normal control of mouse kidney. (B-D) Pronounced histopathological abnormalities are seen in mice treated with cisplatin (15 mg/kg body weight). (B) Congestion and partial atrophy of glomeruli in the cortex, (C) congestion and mild tubular degeneration in the cortico-medullary junction, (D) congestion and perarterial leucocytic aggregation in the medullary portion of the kidney. (E) Normal renal tubules in the cortico-medullary junction and normal collecting tubules (F) normal renal cortex be observed in the kidney of the MTN.5-AIQ-treated group. (G&H) normal hepatic cords with normal hepatocytes in control group. (I&J) Pronounced histopathological abnormalities are seen in mice treated with cisplatin (15 mg/kg body weight). (I) Swelling and mild vascular degeneration in hepatocytes, (J) congestion of both central and portal vein together with mononuclear aggregation. (K) Livers of MTN.5AIQ-treated mice shows nearly normal hepatic cords with normal hepatocytes and sinusoids. Scale bar=100 μ m. MTN.5-AIQ; magnetic thermoresponsive nanocomposite loaded with 5-aminoisoquinoline.....	105
<i>Figure 4.14. Cytotoxicity measurement of MTN and MTN.5-AIQ on Caco-2 cells; Caco-2 cells were incubated with different doses of either MTN unloaded or loaded composites. Twenty four hours later, cell viability was determined via MTT assay. MTN; magnetic thermoresponsive.....</i>	107

LIST OF TABLES

List of tables

Table 3.1 MTNs and drug weights and their ratios

Table (4-1) Lattice parameters value of SPIONs 80

Table (4-2): iron and oxygen weight ratios in maghemite from EDX analysis82

Table (4-3):Atomic weight and weight ratio of elements in MTN.....82

Table (4-4): Crystallite parameter calculated from SAED and XRD pattern.....84

Table (4-5): Magnetic parameter of IONPs and MTN samples.....93

Table (4-6): SAR values measure at different parameters in this study and
literature98

Table (4-7): Drug uptake and drug loading efficiency of MTN.5-AIQ
samples.....99